Literature DB >> 8066447

A specific inhibitor of the epidermal growth factor receptor tyrosine kinase.

D W Fry1, A J Kraker, A McMichael, L A Ambroso, J M Nelson, W R Leopold, R W Connors, A J Bridges.   

Abstract

A small molecule called PD 153035 inhibited the epidermal growth factor (EGF) receptor tyrosine kinase with a 5-pM inhibition constant. The inhibitor was specific for the EGF receptor tyrosine kinase and inhibited other purified tyrosine kinases only at micromolar or higher concentrations. PD 153035 rapidly suppressed autophosphorylation of the EGF receptor at low nanomolar concentrations in fibroblasts or in human epidermoid carcinoma cells and selectively blocked EGF-mediated cellular processes including mitogenesis, early gene expression, and oncogenic transformation. PD 153035 demonstrates an increase in potency over that of other tyrosine kinase inhibitors of four to five orders of magnitude for inhibition of isolated EGF receptor tyrosine kinase and three to four orders of magnitude for inhibition of cellular phosphorylation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8066447     DOI: 10.1126/science.8066447

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  120 in total

1.  p53 induction of heparin-binding EGF-like growth factor counteracts p53 growth suppression through activation of MAPK and PI3K/Akt signaling cascades.

Authors:  L Fang; G Li; G Liu; S W Lee; S A Aaronson
Journal:  EMBO J       Date:  2001-04-17       Impact factor: 11.598

2.  Inhibition of fast sodium current in rabbit ventricular myocytes by protein tyrosine kinase inhibitors.

Authors:  Yanggan Wang; Mary B Wagner; Rajiv Kumar; Jun Cheng; Ronald W Joyner
Journal:  Pflugers Arch       Date:  2003-04-26       Impact factor: 3.657

3.  Heparin-binding ligands mediate autocrine epidermal growth factor receptor activation In skin organ culture.

Authors:  S Stoll; W Garner; J Elder
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

4.  The mitogenic potential of heparin-binding epidermal growth factor in the human endometrium is mediated by the epidermal growth factor receptor and is modulated by tumor necrosis factor-alpha.

Authors:  Katya Chobotova; Mary-Elizabeth Muchmore; Janet Carver; Hyung-J Yoo; Sanjiv Manek; William J Gullick; David H Barlow; Helen J Mardon
Journal:  J Clin Endocrinol Metab       Date:  2002-12       Impact factor: 5.958

Review 5.  Understanding resistance to EGFR inhibitors-impact on future treatment strategies.

Authors:  Deric L Wheeler; Emily F Dunn; Paul M Harari
Journal:  Nat Rev Clin Oncol       Date:  2010-06-15       Impact factor: 66.675

6.  Domain-based biosensor assay to screen for epidermal growth factor receptor modulators in live cells.

Authors:  Christophe Antczak; Alun Bermingham; Paul Calder; Dmitry Malkov; Keming Song; John Fetter; Hakim Djaballah
Journal:  Assay Drug Dev Technol       Date:  2012-01-26       Impact factor: 1.738

7.  Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth.

Authors:  Paul L Leong; Genevieve A Andrews; Daniel E Johnson; Kevin F Dyer; Sichuan Xi; Jeffrey C Mai; Paul D Robbins; Seshu Gadiparthi; Nancy A Burke; Simon F Watkins; Jennifer Rubin Grandis
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-14       Impact factor: 11.205

8.  Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity.

Authors:  Jiabin An; Matthew B Rettig
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

9.  Suppression of heregulin β signaling by the single N-glycan deletion mutant of soluble ErbB3 protein.

Authors:  Motoko Takahashi; Yoshihiro Hasegawa; Yoshitaka Ikeda; Yoshinao Wada; Michiko Tajiri; Shigeru Ariki; Rina Takamiya; Chiaki Nishitani; Motoko Araki; Yoshiki Yamaguchi; Naoyuki Taniguchi; Yoshio Kuroki
Journal:  J Biol Chem       Date:  2013-10-04       Impact factor: 5.157

10.  Active site labelling of inositol 1,4,5-trisphosphate 3-kinase A by phenylglyoxal.

Authors:  D Communi; R Lecocq; V Vanweyenberg; C Erneux
Journal:  Biochem J       Date:  1995-08-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.